Hims & Hers Health stock falls over 3% as return to operating losses overshadows revenue growth
Hims & Hers Health Inc (HIMS) fell 3.23% after third-quarter results showed accelerating revenue but a return to operating losses, with new product expansion and subscriber declines adding to cautious sentiment. The move is supported by broad downside pressure, as the stock remains below key moving averages and technically vulnerable.
Highlights
- Hims & Hers Health revenue grew 49% to $890.4 million in the third quarter, but the company posted a $66.1 million operating loss and lower gross margin at 57%.
- Subscriber count increased 13% year-over-year to 2.8 million with a sequential decline of 100,000 due to reduced marketing and brand transition, as the company expanded its weight-loss drug offerings including Zepbound.
- Shares of Hims & Hers Health trade below key moving averages with bearish momentum, expected to range between $16.75 and $19.16 over the next five sessions with a high probability of further downside.
Mixed subscriber trend and new drug lineup amid profit reversal
Hims & Hers Health reported third-quarter revenue growth of 49% to $890.4 million, which came in slightly below estimates. The company recorded an operating loss of $66.1 million for the quarter, reversing a profit posted a year ago, and gross margin fell to 57% from 74%. Subscriber numbers increased by 13% year-over-year to 2.8 million, while management cited a loss of 100,000 subscribers from the previous quarter due to scaled-back marketing and brand transitions. Hims & Hers Health further expanded its weight-loss drug lineup, securing access to Eli Lilly's Zepbound, and outlined plans to produce peptide ingredients pending regulatory clearance, though price action has remained under broader selling pressure.
Momentum deteriorates as oversold indicators meet ongoing pressure
HIMS is currently trading below its 20-day ($25.30), 50-day ($27.43), and 200-day ($26.63) moving averages, highlighting persistent downside momentum across all timeframes. The 50-day and 200-day moving average alignment still hints at a longer-term bullish structure, but near-term signals are negative. Immediate resistance is at $18.46, with support at $16.75. Momentum indicators reinforce the bearish tone, as MACD (-3.36) and ADX (26.25) indicate ongoing selling pressure. RSI is neutral, while both Stochastic RSI and the Commodity Channel Index (CCI) sit in the oversold zone, which suggests the recent decline may be approaching exhaustion or could see a short-term rebound. Bull/Bear Power is negative, confirming sellers are controlling momentum, and the Awesome Oscillator is negative as well. Persistent price weakness after an initial upside gap mirrors these broader negative signals, with volatility high at 3.68%.
Earlier, analysts noted that Hims & Hers Health faced ongoing downside momentum and persistent technical weakness despite growth initiatives. The latest results reinforce this bearish outlook, placing increased focus on support at $16.75 as the critical level for potential downside acceleration in the coming sessions.